Personalised mRNA vaccine cuts melanoma recurrence risk
‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows
Sunday, 25 October 2026
Photo by National Cancer Institute on Unsplash
Warm-up
- What do you think makes a treatment truly personalised?
- How do clinical trials help doctors trust new medicines?
- When should regulators approve a treatment early, and why?
Vocabulary
- melanoma
- A serious type of skin cancer that can spread to other parts of the body.
- recurrence
- The return of a disease after a period with no signs of it.
- personalised
- Designed for one person based on their unique medical information.
- immunotherapy
- A treatment that helps the immune system find and attack disease.
- mutation
- A change in a gene that can alter how cells behave.
- phase
- A stage in clinical testing used to check a treatment’s safety and benefit.
- regulator
- An official body that approves or controls how medicines are used.
- congress
- A large formal meeting of specialists, often held annually.
Reading
Listen to this story
British EnglishAn Australian-led phase III trial has reported strong results for a personalised mRNA vaccine for melanoma, called intismeran. The study enrolled 1,137 patients whose melanoma had been removed but who faced a high risk of recurrence. Everyone received the immunotherapy drug pembrolizumab for twelve months; some also received intismeran. After two years, the combination reduced the risk of recurrence or death by 42% compared with pembrolizumab alone. In the same period, 82% on the combination were alive and recurrence-free, versus 70% on immunotherapy alone.
Researchers say the vaccine is tailored to target up to 34 tumour mutations in each patient. Results are to be presented at the European Society for Medical Oncology’s congress in Madrid and have been accepted by the New England Journal of Medicine. Prof Georgina Long of the Melanoma Institute Australia called the findings a foundational shift towards more personalised use of the immune system.
Approval would require regulators to review longer-term outcomes; the manufacturers say it is too soon to know whether overall survival improves beyond two years. Even so, the phase III data indicate the combination works better than immunotherapy alone.
Comprehension
- What is the name of the personalised melanoma vaccine?
- How many patients took part in the phase III trial?
- What treatment did every participant receive for twelve months?
- By how much did the combination cut risk at two years?
- Where are the results to be presented?
Grammar focus
Be to / be set to for official arrangements
Use be to / be set to for official or scheduled plans and announcements. Form: am/is/are + to + base verb OR am/is/are + set to + base verb. Common in news for timetabled or announced events. (Examples constructed.)
- Results are to be presented at the Madrid congress.
- Results are set to be presented at the Madrid congress.
Grammar exercise
Complete with be to / be set to: conjugate the verb in brackets.
- According to the program, teams (share) ___ safety data.
- By order, the congress (host) ___ melanoma sessions.
- Manufacturers (announce) ___ next steps later.
- Researchers (submit) ___ full findings to a journal.
- Trial updates (release) ___ at ESMO in Madrid.
Discussion
- Should health systems fund personalised cancer vaccines? Why or why not?
- How much evidence is enough before regulators approve a new therapy?
- What ethical issues can arise with bespoke treatments like this?
- How can countries share trial benefits across populations?
Vocabulary, reading, and exercises with instant feedback
Spotted a mistake in this lesson? Tell us.